Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study
Yazar
Kaya, Handan
Yazici, Hulya
Iyikesici, Salih
Serdar, Turhal N.
Guney, Nese
Basaran, Gul Atalay
Saip, Pinar
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]